Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CWP-0403 (Anagliptin) in Type 2 DM Patients
NCT01529528Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anagliptin in type 2 diabetes mellitus (T2DM), sponsored by JW Pharmaceutical Corporation. Started May 2011; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01529528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01529528.